Abstract
Objective
The FRUIT-RCT concluded that low-molecular-weight heparin added to aspirin compared
to treatment with aspirin alone is beneficial in the prevention of early-onset hypertensive
disorders of pregnancy (HD) in women with inheritable thrombophilia and prior HD and/or
a small-for-gestational age (SGA) infant leading to delivery before 34 weeks gestation.
The aim of this study is to answer the question whether aspirin resistance is associated
with recurrent HD.
Study design
Women with and without recurrent HD matched for age, study arm, and chronic hypertension
were invited for this follow-up study 6–16 years after they participated in the FRUIT-RCT.
Aspirin resistance was tested after 10 days of aspirin intake using three complementary tests: PFA-200, VerifyNow® and serum thromboxane B2 (TXB2). An independent t-test, Mann-Whitney U test, Fisher’s Exact test and Chi2 test were used for the statistical analyses.
Results
Thirteen of 24 women with recurrent HD and 16 of 24 women without recurrent HD participated.
The prevalence of laboratory aspirin resistance was 34.5% according to the PFA-200,
3.4% according to the VerifyNow® and 24.1% according to TXB2. The prevalence of aspirin resistance by any test was 51.7%. Aspirin resistance per
individual test did not differ between women with and without recurrent HD. Aspirin
resistance measured by any test occurred more frequently in women without recurrent
HD (p < 0.01), irrespective of low-molecular-weight heparin.
Conclusions
No relation could be demonstrated between recurrent HD and aspirin resistance per
test, measured up to 16 years after pregnancy. On the contrary, complementary aspirin
resistance measurements were encountered more frequently in women without recurrent
HD.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Obstetrics and Gynecology and Reproductive BiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT.J Thromb Haemost. 2012; 10: 64-72
- Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a rebuttal.J Thromb Haemost. 2012; 10: 1195
- The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin.Acta Cardiol. 2012; 67: 445-448
- Aspirin resistance: moving forward with multiple definitions, different assays, and a clinical imperative.Am J Clin Pathol. 2005; 123: S125-S132
- Prevalence of aspirin resistance measured by PFA-100.Int J Cardiol. 2005; 101: 71-76
- Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease.J Geriatr Cardiol. 2013; 10: 21-27
- Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.J Thromb Haemost. 2014; 12: 736-747
- Evaluation of platelet function using PFA-100(R) in patients treated with Acetylsalicylic acid and qualified for Trauma and Orthopedic surgery procedures.Platelets. 2016; : 1-7
- Is testing for aspirin response worthwhile in high-risk pregnancy?.Eur J Obstet Gynecol Reprod Biol. 2011; 157: 38-42
- Low-dose ASA response using the PFA-100 in women with high-risk pregnancy.J Obstet Gynaecol Can. 2009; 31: 1022-1027
- Aspirin resistance may be associated with adverse pregnancy outcomes.Neuro Endocrinol Lett. 2011; 32: 334-339
http://www.healthcare.siemens.nl/hemostasis/systems/innovance-pfa-200.
- Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.J Thromb Haemost. 2013; 11: 379-381
- Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different pharmaceutical formulations.Cardiovasc Drugs Ther. 2014; 28: 323-329
- Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?.Stroke. 2005; 36: 276-280
- Low dose aspirin and pregnancy: how important is aspirin resistance?.BJOG. 2016;
- Platelet reactivity changes significantly throughout all trimesters of pregnancy compared with the nonpregnant state: a prospective study.BJOG. 2013;
- Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women.Am J Obstet Gynecol. 2004; 190: 1128-1134
- Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy.Thromb Haemost. 1996; 75: 346-351
- Aspirin resistance and compliance with therapy.Cardiovasc Ther. 2011; 29: 301-307
- A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.Eur Heart J. 2007; 28: 1702-1708
- Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH.J Thromb Haemost. 2013;
Article info
Publication history
Published online: December 22, 2016
Accepted:
December 19,
2016
Received in revised form:
December 1,
2016
Received:
September 13,
2016
Identification
Copyright
© 2016 Elsevier Ireland Ltd. All rights reserved.
